GS030, GenSight’s gene therapy product candidate to treat Retinitis Pigmentosa (RP), will be presented in the Paper Session – On Demand.
GS030 – Optogenetics in Retinitis Pigmentosa
Paper Title: Optogenetic GS030 Therapy in Subjects with Retinitis Pigmentosa: Safety and Tolerability Up to Two Years After Treatment Administration in the Phase 1/2a PIONEER Study
Presenting Author: Jose Alain Sahel, MD, Chairman, University of Pittsburgh Medical Center, Pittsburgh, United States
Paper session: Inherited Retinal Disease – On-Demand